Dan Ferris decode of his must have immediately stockSo Dan Ferris did share his pick with the paid Members within his Extreme Value newsletter on Stansbury But he also teased to the folks like me with a 49$ membership. Shockingly, its a doozy. It was up 20% today and isnt even close to being on the radar yet. I would be happy to […]
Articles
As
Lots and lots and lots of you have been asking me about the big “cancer presentation” that the Stansberry folks made last night, which apparently was a combination of Dr. David Eifrig’s medical advice and forecasting and Dave Lashmet’s hinting about his “medical breakthrough” stock… so let’s get to it. I did not watch or […]
Lots of readers have been sending questions our way about Porter Stansberry’s new high-cost Stansberry Venture Value newsletter, which is his attempt to build a service that essentially recommends small cap value stocks for long-term compounding value. An admirable goal, and I guess we’ll start to learn in the coming year or two how it’s […]
Dave Lashmet is sending around an ad for his Stansberry Venture service that he says highlights an investment that is “Three Times Better Than Any Opportunity I’ve Ever Found.” So that sounds pretty good, right? One nice thing about being an investment chatterer is that you can have a short memory — each idea that […]
Dave Lashmet has teased a handful of biotech stocks since starting the Stansberry Venture service a couple years ago, and they usually get a lot of attention from our readers — so the new ad from Lashmet today has been forwarded to me dozens of times already. And while I’m not sure we’ll be able […]
Stansberry Venture is a high-end ($5,000/yr) newsletter that focuses on small “breakthrough” type companies, so far mostly in biotech and technology as far as I’ve seen. It’s the heir, roughly speaking, of Stansberry’s old Phase 1 newsletter that used to often pitch biotech, tech and junior mining stocks. It’s helmed by Dave Lashmet, who was […]
That’s a mysterious headline, right? The pitch we’re looking at today is from Dave Lashmet at Stansberry, who’s selling his Stansberry Venture newsletter for $5,000 — and the carrot he’s dangling to get you to subscribe is this “most disruptive biotech discovery” … which, it turns out, is a form of radiation therapy that, in […]
We’ve got a good teaser to solve today, but first — a quick plea: This will be our final week of “Gumshoe Gives Back” this year — we will be donating at least half of all the membership contributions received through the rest of this week (until the end of the day on Friday, 12/12) […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
No, we ...
Is this the same drug being pushed to sell Stansberry Venture...
Aside from being a Stansbery Alliance member, did you subscribe to Stansberry Venture Tech too? You're talking about t...
Just being a Stansberry Alliance Member does not allow you access to Stansberry Venture Tech subscription of Dave La...
I like your analysis Travis, but I am a Stansberry Alliance member and I can tell you it is not RYTM. It is a VERY TINY...
Maybe ENTA (Enanta) Around $50 and doing something in the obesity field if I understand correctly. https://www.enanta.co...
Ah, good old 'Stansberry Venture Value' & their $1897. P/yr (Please no refunds) teasers. I have to say like most of ...
i am still having problems try to access stansberry venture value..if you cant help me, iwant a refunf!...
I am new to stansberry and so far I'm really impressed with the write ups. I like the full service brokerage program and...
Hi Travis, Hope all is well. During the recent discussion of their new offering, Stansberry Venture ...
I signed up for Stansberry Venture and was told I could get a deal at $5,000 for lifetime (normally $8.500 for a lifetim...
Great report; I love your logical approach and completely agree with your conclusions! I was wondering if you have seen...
Re: biotech mergers and acquisitions Although the surge in M&A activity has some observors warning of a "bubble" in ...
"One more thing!" -- Colombo I received this over the weekend from S & A Master Series: The four new gram-negat...
The Stansberry Venture group is teasing an antibiotic play that I imagine is one of ours. Any idea which one? http://pr...
We don't publish Stansberry Venture, but we did write about one of their ads here: http://www.stockgumshoe.com/reviews/s...
I AM A SUB SCRIBER TO YOUR PERIODICAL AND AM VERY INTERESTED IN YOUR STANSBERRY VENTURE. HOW DO I INVEST IN THIS COMPANY...
Careful about assuming the cause for a move -- there are many, many more people reading this free article than there are...